Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Taysha Gene Therapies, Inc. (TSHA)
USD6.00
+0.30 (+5.34%)
US NASDAQ Healthcare Biotechnology
Address
3000 Pegasus Park Drive 75247
Dallas, TX, US
Dallas, TX, US
CEO
Sean Nolan
Website
tayshagtx.com
IPO
2020-09-24
CIK 1806310 ISIN US8776191061
Description
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.00
+0.30 (+5.34%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.18
Float Shares
235.59M
Free Float %
82.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.44% | -2.00% | +52.56% | +47.31% | +57.11% | +24.55% | +195.26% | +920.26% | -66.37% | -71.53% | -71.53% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (16 ratings, all time)
Buy
Price Targets & DCF
Current price
6.00
Low
11.00
+83.2%
Consensus
11.80
+96.5%
Median
11.00
+83.2%
High
13.00
+116.5%
DCF (Unlevered)
0.63
-89.5%
DCF (Levered)
0.25
-95.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 11 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 8 |
11.13
+85.4%
|
| All Time | 15 |
13.50
+124.8%
|
Quality scores
Altman Z-Score
7.68
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+17.3% ★ Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+5.6% Q1'26: -50.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,166.1%
-
EBIT margin Biotechnology: +0.0%-1,114.6%
-
ROIC Biotechnology: -16.1%— Q1'26: +371.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+27.8% Q1'26: +36.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.17× Q1'26: -0.10× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 7 EPS Ana. |
Dec 2027 7 Rev. Ana. 6 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.50M
est: 8.18M (-69.4%)
|
15.45M
est: 14.16M (+9.1%)
|
8.33M
est: 8.25M (+1.1%)
|
9.77M
est: 5.87M (+66.4%)
|
2.00M
2.00M – 2.00M
-65.9% YoY
|
138.14M
138.14M – 138.14M
+6,807.2% YoY
|
150.22M
149.09M – 151.35M
+8.7% YoY
|
479.49M
479.49M – 479.49M
+219.2% YoY
|
957.88M
957.88M – 957.88M
+99.8% YoY
|
| EBITDA |
-159.73M
est: -1.64M (-9,661.2%)
|
-105.20M
est: -8.49M (-1,138.5%)
|
-87.95M
est: -4.95M (-1,677.7%)
|
-107.79M
est: -3.52M (-2,959.3%)
|
-1.20M
-1.20M – -1.20M
+65.9% YoY
|
-82.89M
-82.89M – -82.89M
-6,807.2% YoY
|
-90.13M
-90.81M – -89.45M
-8.7% YoY
|
-287.69M
-287.69M – -287.69M
-219.2% YoY
|
-574.73M
-574.73M – -574.73M
-99.8% YoY
|
| EBIT |
-162.22M
est: -1.64M (-9,813.2%)
|
-106.57M
est: -8.49M (-1,154.7%)
|
-89.20M
est: -4.95M (-1,702.9%)
|
-108.93M
est: -3.52M (-2,991.8%)
|
-1.20M
-1.20M – -1.20M
+65.9% YoY
|
-82.89M
-82.89M – -82.89M
-6,807.2% YoY
|
-90.13M
-90.81M – -89.45M
-8.7% YoY
|
-287.69M
-287.69M – -287.69M
-219.2% YoY
|
-574.73M
-574.73M – -574.73M
-99.8% YoY
|
| Net Income |
-166.01M
est: -736.34M (+77.5%)
|
-111.57M
est: -238.60M (+53.2%)
|
-89.30M
est: -120.04M (+25.6%)
|
-109.00M
est: -113.43M (+3.9%)
|
-173.98M
-183.07M – -131.26M
-53.4% YoY
|
-97.04M
-129.39M – -64.69M
+44.2% YoY
|
-101.77M
-181.72M – 17.87M
-4.9% YoY
|
72.89M
72.89M – 72.89M
+171.6% YoY
|
319.71M
319.71M – 319.71M
+338.6% YoY
|
| SGA |
34.87M
est: 34.95M (-0.2%)
|
30.05M
est: 67.12M (-55.2%)
|
28.95M
est: 39.29M (-26.3%)
|
33.87M
est: 27.98M (+21.1%)
|
9.53M
9.53M – 9.53M
-65.9% YoY
|
658.19M
658.19M – 658.19M
+6,807.2% YoY
|
715.72M
710.35M – 721.10M
+8.7% YoY
|
2.28B
2.28B – 2.28B
+219.2% YoY
|
4.56B
4.56B – 4.56B
+99.8% YoY
|
| EPS |
-3.78
est: -2.94 (-28.4%)
|
-0.96
est: -0.75 (-28.6%)
|
-0.36
est: -0.37 (+2.8%)
|
-0.34
est: -0.36 (+5.5%)
|
-0.48
-0.57 – -0.41
-32.2% YoY
|
-0.32
-0.40 – -0.20
+32.6% YoY
|
-0.26
-0.57 – 0.06
+19.1% YoY
|
0.23
0.23 – 0.23
+187.9% YoY
|
1.00
1.00 – 1.00
+338.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-111.45M
OE per share TTM
-0.32
Owner's Yield
-5.00%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
358.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
35
Total invested
23.79M
Insider transactions (90d)
0
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Avoro Capital Advisors LLC | 23.09M | 9.99% | 23.09M | — | 23.09M | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 2 | Behzad Aghazadeh | 23.09M | 9.99% | 23.09M | — | 23.09M | — | IN | Delaware | 2024-11-14 | ↗ |
| 3 | Peter Kolchinsky | 18.69M | 9.99% | — | 18.69M | — | 18.69M | HC, IN | Delaware | 2023-08-25 | ↗ |
| 4 | RA Capital Healthcare Fund, L.P. | 18.69M | 9.99% | — | 18.69M | — | 18.69M | PN | Delaware | 2023-08-25 | ↗ |
| 5 | RA Capital Management, L.P. | 18.69M | 9.99% | — | 18.69M | — | 18.69M | IA, PN | Delaware | 2023-08-25 | ↗ |
| 6 | Rajeev Shah | 18.69M | 9.99% | — | 18.69M | — | 18.69M | HC, IN | Delaware | 2023-08-25 | ↗ |
| 7 | RTW Investments, LP | 18.51M | 9.80% | — | 18.51M | — | — | IA, PN | Delaware | 2024-02-14 | ↗ |
| 8 | Roderick Wong, M.D. | 18.51M | 9.80% | — | 18.51M | — | — | HC, IN | United States | 2024-02-14 | ↗ |
| 9 | Koh, Bong | 14.44M | 7.70% | — | 14.44M | — | — | IN | Delaware | 2023-08-28 | ↗ |
| 10 | Shah, Nimish | 14.44M | 7.70% | — | 14.44M | — | — | IN | Delaware | 2023-08-28 | ↗ |
| 11 | VHCP Co-Investment Holdings III, LLC | 14.44M | 7.70% | — | 14.44M | — | — | OO | Delaware | 2023-08-28 | ↗ |
| 12 | VHCP Management EG, LLC | 14.44M | 7.70% | — | 14.44M | — | — | OO | Delaware | 2023-08-28 | ↗ |
| 13 | VHCP Management III, LLC | 14.44M | 7.70% | — | 14.44M | — | — | OO | Delaware | 2023-08-28 | ↗ |
| 14 | Venrock Healthcare Capital Partners EG, L.P. | 14.44M | 7.70% | — | 14.44M | — | — | PN | Delaware | 2023-08-28 | ↗ |
| 15 | Venrock Healthcare Capital Partners III, L.P. | 14.44M | 7.70% | — | 14.44M | — | — | PN | Delaware | 2023-08-28 | ↗ |
| 16 | (1) BlackRock, Inc. | 13.52M | 6.60% | 13.38M | — | 13.52M | — | HC | Delaware | 2024-11-08 | ↗ |
| 17 | Chen Yu | 11.11M | 5.90% | — | 11.11M | — | 11.11M | IN | Delaware | 2023-08-25 | ↗ |
| 18 | TCG Crossover Fund I, L.P. | 11.11M | 5.90% | — | 11.11M | — | 11.11M | PN | Delaware | 2023-08-25 | ↗ |
| 19 | TCG Crossover GP I, LLC | 11.11M | 5.90% | — | 11.11M | — | 11.11M | OO | Delaware | 2023-08-25 | ↗ |
| 20 | RA Session II | 9.43M | 25.50% | 9.15M | 282.2K | 9.15M | 10.00 | IN | United States | 2020-10-05 | ↗ |
| 21 | Astellas Pharma Inc. | 7.27M | 11.60% | — | 7.27M | — | 7.27M | CO | — | 2022-10-31 | ↗ |
| 22 | Astellas US Holding, Inc. | 7.27M | 11.60% | — | 7.27M | — | 7.27M | CO | — | 2022-10-31 | ↗ |
| 23 | Audentes Therapeutics, Inc. | 7.27M | 11.60% | — | 7.27M | — | 7.27M | CO | — | 2022-10-31 | ↗ |
| 24 | Paul B. Manning | 5.30M | 14.30% | 3.28M | 2.02M | 3.28M | 10.00 | IN | United States | 2020-10-05 | ↗ |
| 25 | The Paul B. Manning Revocable Trust dated May 10, 2000 | 3.28M | 8.90% | 3.28M | — | 3.28M | 10.00 | OO | Virginia | 2020-10-05 | ↗ |
| 26 | BKB Growth Investments, LLC | 2.02M | 5.50% | 2.02M | — | 2.02M | 10.00 | OO | Delaware | 2020-10-05 | ↗ |
| 27 | The Board of Regents of the University of Texas System 74-6000203 | 1.16M | 3.01% | — | 1.16M | — | 1.16M | OO | Texas | 2021-09-24 | ↗ |
| 28 | The University of Texas/Texas A&M Investment Management Company 74-2765082 | 1.16M | 3.01% | — | 1.16M | — | 1.16M | IA | Texas | 2021-09-24 | ↗ |
| 29 | RA Session II, as Trustee of the Session 2020 Annuity Trust I | 141.1K | 0.40% | — | 141.1K | — | 10.00 | OO | Texas | 2020-10-05 | ↗ |
| 30 | RA Session II, as Trustee of the Session 2020 Annuity Trust II | 141.1K | 0.40% | — | 141.1K | — | 10.00 | OO | Texas | 2020-10-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
35
-168 vs prev Q
New positions
4
Closed positions
165
Increased
15
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1.33M +1.3M (+100.0%) | 7.32B +7.3B (+100.0%) | 0.38% +0.377 pp | 5.25% +5.248 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 23.56M +— (+0.0%) | 129.56M +52.5M (+68.2%) | 6.67% -1.238 pp | 1.33% +0.378 pp | USD2.70 +103.7% | 10 qtrs — |
| 3 | AVORO CAPITAL ADVISORS LLC | 21.70M +— (+0.0%) | 119.35M +48.4M (+68.2%) | 6.14% -1.140 pp | 1.15% +0.230 pp | USD2.77 +98.6% | 10 qtrs — |
| 4 | BLACKROCK, INC. | 18.64M +2.3M (+13.9%) | 102.54M +49.0M (+91.6%) | 5.28% -0.215 pp | 0.00% +0.001 pp | USD2.64 +108.3% | 6 qtrs — |
| 5 | MORGAN STANLEY | 18.08M -1.2M (-6.4%) | 99.43M +36.3M (+57.5%) | 5.12% -1.362 pp | 0.01% +0.002 pp | USD2.28 +141.2% | 21 qtrs — |
| 6 | RTW INVESTMENTS, LP | 16.40M -8.0M (-32.7%) | 90.19M +10.6M (+13.3%) | 4.64% -3.532 pp | 0.90% -0.078 pp | USD2.22 +147.7% | 10 qtrs — |
| 7 | VESTAL POINT CAPITAL, LP | 13.75M +8.3M (+150.0%) | 75.63M +57.6M (+320.5%) | 3.89% +2.046 pp | 2.57% +1.759 pp | USD4.40 +25.0% | 3 qtrs — |
| 8 | GOLDMAN SACHS GROUP INC | 13.69M +309.0K (+2.3%) | 75.31M +31.5M (+72.1%) | 3.88% -0.616 pp | 0.01% +0.004 pp | USD2.45 +124.5% | 9 qtrs — |
| 9 | FMR LLC | 13.53M -1.1M (-7.3%) | 74.41M +26.7M (+55.9%) | 3.83% -1.068 pp | 0.00% +0.001 pp | USD4.01 +37.2% | 22 qtrs — |
| 10 | VANGUARD GROUP INC | 13.27M +418.2K (+3.3%) | 72.97M +31.0M (+73.7%) | 3.76% -0.557 pp | 0.00% +0.000 pp | USD3.98 +38.2% | 22 qtrs — |
| 11 | STATE STREET CORP | 10.79M +3.6M (+49.1%) | 59.35M +35.7M (+150.8%) | 3.05% +0.626 pp | 0.00% +0.001 pp | USD3.52 +56.3% | 21 qtrs — |
| 12 | SIREN, L.L.C. | 10.13M -884.8K (-8.0%) | 55.71M +19.7M (+54.7%) | 2.87% -0.829 pp | 1.66% +0.253 pp | USD2.09 +163.2% | 6 qtrs — |
| 13 | OCTAGON CAPITAL ADVISORS LP | 8.86M -207.6K (-2.3%) | 48.73M +19.1M (+64.3%) | 2.51% -0.535 pp | 5.92% +1.422 pp | USD2.14 +157.0% | 10 qtrs — |
| 14 | POLAR CAPITAL HOLDINGS PLC | 7.93M +2.6M (+49.8%) | 43.62M +26.3M (+152.0%) | 2.24% +0.468 pp | 0.17% +0.085 pp | USD3.67 +49.9% | 10 qtrs — |
| 15 | BARCLAYS PLC | 5.54M +5.3M (+2,140.0%) | 30.46M +30.0M (+5,851.6%) | 1.57% +1.485 pp | 0.01% +0.007 pp | USD5.33 +3.2% | 7 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 5.39M +212.5K (+4.1%) | 29.63M +12.7M (+75.1%) | 1.52% -0.212 pp | 0.00% +0.001 pp | USD3.36 +63.7% | 21 qtrs — |
| 17 | D. E. SHAW & CO., INC. | 4.01M +1.3M (+48.3%) | 22.07M +13.2M (+149.4%) | 1.14% +0.228 pp | 0.01% +0.007 pp | USD3.90 +41.0% | 3 qtrs — |
| 18 | BAKER BROS. ADVISORS LP | 4.00M +— (+0.0%) | 22.03M +8.9M (+68.2%) | 1.13% -0.210 pp | 0.13% +0.034 pp | USD2.64 +108.3% | 10 qtrs — |
| 19 | POINT72 ASSET MANAGEMENT, L.P. | 3.87M -3.5M (-47.2%) | 21.28M -2.7M (-11.2%) | 1.10% -1.365 pp | 0.02% -0.016 pp | USD1.74 +216.1% | 4 qtrs — |
| 20 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 3.72M +3.7M (+100.0%) | 20.47M +20.5M (+100.0%) | 1.05% +1.054 pp | 0.03% +0.034 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 21 | AFFINITY ASSET ADVISORS, LLC | 3.30M +300.0K (+10.0%) | 18.15M +8.3M (+85.0%) | 0.93% -0.073 pp | 1.03% +0.180 pp | USD3.41 +61.3% | 3 qtrs — |
| 22 | MILLENNIUM MANAGEMENT LLC | 3.18M -847.3K (-21.0%) | 17.48M +4.3M (+32.8%) | 0.90% -0.451 pp | 0.01% +0.002 pp | USD2.18 +152.3% | 22 qtrs — |
| 23 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2.72M -2.7M (-49.5%) | 14.97M -2.6M (-15.0%) | 0.77% -1.037 pp | 0.19% -0.078 pp | USD2.31 +138.1% | 3 qtrs — |
| 24 | ADAR1 CAPITAL MANAGEMENT, LLC | 2.50M -339.9K (-12.0%) | 13.73M +4.5M (+48.0%) | 0.71% -0.245 pp | 1.01% +0.137 pp | USD2.03 +170.9% | 9 qtrs — |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.90M +56.5K (+3.1%) | 10.47M +4.4M (+73.3%) | 0.54% -0.081 pp | 0.00% +0.001 pp | USD3.19 +72.4% | 21 qtrs — |
| 26 | CITADEL ADVISORS LLC | 1.85M +1.5M (+405.0%) | 10.20M +9.0M (+749.4%) | 0.53% +0.402 pp | 0.00% +0.001 pp | USD4.84 +13.6% | 17 qtrs — |
| 27 | NORGES BANK | 1.84M +1.8M (+100.0%) | 10.11M +10.1M (+100.0%) | 0.52% +0.520 pp | 0.00% +0.001 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 28 | B GROUP, INC. | 1.80M +— (+0.0%) | 9.90M +4.0M (+68.2%) | 0.51% -0.095 pp | 7.31% +2.981 pp | USD1.85 +197.3% | 5 qtrs — |
| 29 | CASDIN CAPITAL, LLC | 1.50M +1.5M (+100.0%) | 8.25M +8.3M (+100.0%) | 0.42% +0.425 pp | 0.51% +0.512 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 30 | INVESCO LTD. | 1.33M +1.1M (+376.3%) | 7.33M +6.4M (+701.2%) | 0.38% +0.283 pp | 0.00% +0.001 pp | USD4.83 +13.9% | 7 qtrs — |
| 31 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.33M -2.0M (-60.1%) | 7.30M -3.6M (-32.9%) | 0.38% -0.741 pp | 0.01% -0.006 pp | USD2.31 +138.1% | 5 qtrs — |
| 32 | RICE HALL JAMES & ASSOCIATES, LLC | 1.27M +692.5K (+119.8%) | 6.99M +5.1M (+269.7%) | 0.36% +0.166 pp | 0.38% +0.282 pp | USD4.49 +22.5% | 2 qtrs — |
| 33 | NORTHERN TRUST CORP | 1.24M -479.2K (-27.9%) | 6.81M +1.2M (+21.3%) | 0.35% -0.226 pp | 0.00% +0.000 pp | USD2.67 +106.0% | 21 qtrs — |
| 34 | PALO ALTO INVESTORS LP | 1.18M -62.8K (-5.0%) | 6.51M +2.4M (+59.7%) | 0.33% -0.083 pp | 0.91% +0.152 pp | USD1.82 +202.2% | 9 qtrs — |
| 35 | BANK OF AMERICA CORP /DE/ | 1.15M -154.6K (-11.8%) | 6.34M +2.1M (+48.3%) | 0.33% -0.113 pp | 0.00% +0.000 pp | USD2.49 +120.9% | 21 qtrs — |
| 36 | ABRDN PLC | 1.02M +1.0M (+100.0%) | 5.62M +5.6M (+100.0%) | 0.29% +0.289 pp | 0.01% +0.009 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 37 | SUPERSTRING CAPITAL MANAGEMENT LP | 980.8K +980.8K (+100.0%) | 5.39M +5.4M (+100.0%) | 0.28% +0.278 pp | 2.89% +2.888 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 38 | EAM INVESTORS, LLC | 823.8K +823.8K (+100.0%) | 4.53M +4.5M (+100.0%) | 0.23% +0.233 pp | 0.50% +0.505 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 39 | QUANTUM PRIVATE WEALTH, LLC | 819.7K -2.4K (-0.3%) | 4.51M +1.8M (+67.7%) | 0.23% -0.044 pp | 1.32% +0.531 pp | USD3.63 +51.5% | 17 qtrs — |
| 40 | SG AMERICAS SECURITIES, LLC | 781.5K +748.5K (+2,271.8%) | 4.30M +4.2M (+3,879.6%) | 0.22% +0.210 pp | 0.01% +0.005 pp | USD5.37 +2.4% | 6 qtrs — |
| 41 | JPMORGAN CHASE & CO | 774.4K +478.2K (+161.4%) | 4.26M +3.3M (+339.7%) | 0.22% +0.120 pp | 0.00% +0.000 pp | USD4.36 +26.1% | 21 qtrs — |
| 42 | SANDS CAPITAL VENTURES, LLC | 724.9K +— (+0.0%) | 3.99M +1.6M (+68.2%) | 0.21% -0.038 pp | 0.77% +0.250 pp | USD18.62 -70.5% | 18 qtrs — |
| 43 | WELLINGTON MANAGEMENT GROUP LLP | 711.2K +143.2K (+25.2%) | 3.91M +2.1M (+110.6%) | 0.20% +0.011 pp | 0.00% +0.000 pp | USD2.64 +108.3% | 6 qtrs — |
| 44 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 704.0K -412.7K (-37.0%) | 3.87M +220.5K (+6.0%) | 0.20% -0.176 pp | 0.17% +0.016 pp | USD2.22 +147.7% | 7 qtrs — |
| 45 | BANK OF NEW YORK MELLON CORP | 624.4K -472.0 (-0.1%) | 3.43M +1.4M (+68.1%) | 0.18% -0.033 pp | 0.00% +0.000 pp | USD2.43 +126.3% | 10 qtrs — |
| 46 | NUVEEN, LLC | 545.3K +38.1K (+7.5%) | 3.00M +1.3M (+80.8%) | 0.15% -0.016 pp | 0.00% +0.000 pp | USD1.82 +202.2% | 4 qtrs — |
| 47 | ALLY BRIDGE GROUP (NY) LLC | 500.0K +500.0K (+100.0%) | 2.75M +2.8M (+100.0%) | 0.14% +0.142 pp | 2.86% +2.865 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 48 | WOODLINE PARTNERS LP | 500.0K +— (+0.0%) | 2.75M +1.1M (+68.2%) | 0.14% -0.026 pp | 0.01% +0.003 pp | USD2.27 +142.3% | 7 qtrs — |
| 49 | DIMENSIONAL FUND ADVISORS LP | 490.5K +145.3K (+42.1%) | 2.70M +1.6M (+140.1%) | 0.14% +0.023 pp | 0.00% +0.000 pp | USD3.93 +39.9% | 2 qtrs — |
| 50 | CAPTION MANAGEMENT, LLC | 490.7K +490.7K (+100.0%) | 2.70M +2.7M (+100.0%) | 0.14% +0.139 pp | 0.02% +0.019 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 51 | SQUAREPOINT OPS LLC | 471.6K +273.2K (+137.7%) | 2.59M +1.9M (+299.9%) | 0.13% +0.067 pp | 0.00% +0.002 pp | USD4.36 +26.1% | 11 qtrs — |
| 52 | ACUTA CAPITAL PARTNERS, LLC | 454.8K +— (+0.0%) | 2.50M +1.0M (+68.2%) | 0.13% -0.024 pp | 1.70% +0.162 pp | USD2.31 +138.1% | 10 qtrs — |
| 53 | HRT FINANCIAL LP | 409.3K +409.3K (+100.0%) | 2.25M +2.3M (+100.0%) | 0.12% +0.116 pp | 0.01% +0.007 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 54 | UBS GROUP AG | 383.0K -256.3K (-40.1%) | 2.11M +16.0K (+0.8%) | 0.11% -0.106 pp | 0.00% +0.000 pp | USD2.71 +103.0% | 22 qtrs — |
| 55 | SPHERA FUNDS MANAGEMENT LTD. | 368.1K -40.0K (-9.8%) | 2.02M +690.2K (+51.7%) | 0.10% -0.033 pp | 0.39% +0.110 pp | USD2.31 +138.1% | 3 qtrs — |
| 56 | TWO SIGMA INVESTMENTS, LP | 351.1K +285.0K (+431.2%) | 1.93M +1.7M (+793.4%) | 0.10% +0.077 pp | 0.00% +0.002 pp | USD4.99 +10.2% | 5 qtrs — |
| 57 | RAFFERTY ASSET MANAGEMENT, LLC | 344.8K +105.0K (+43.8%) | 1.90M +1.1M (+141.8%) | 0.10% +0.017 pp | 0.01% +0.004 pp | USD3.62 +51.9% | 5 qtrs — |
| 58 | BOOTHBAY FUND MANAGEMENT, LLC | 309.5K -106.1K (-25.5%) | 1.70M +343.1K (+25.2%) | 0.09% -0.052 pp | 0.03% +0.006 pp | USD3.27 +68.2% | 2 qtrs — |
| 59 | HENNION & WALSH ASSET MANAGEMENT, INC. | 308.5K +308.5K (+100.0%) | 1.70M +1.7M (+100.0%) | 0.09% +0.087 pp | 0.06% +0.059 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 60 | WELLS FARGO & COMPANY/MN | 305.1K +160.0K (+110.3%) | 1.68M +1.2M (+253.7%) | 0.09% +0.038 pp | 0.00% +0.000 pp | USD3.98 +38.2% | 17 qtrs — |
| 61 | CAPRICORN FUND MANAGERS LTD | 300.0K +300.0K (+100.0%) | 1.65M +1.7M (+100.0%) | 0.08% +0.085 pp | 0.40% +0.398 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 62 | COLONY GROUP, LLC | 295.5K +295.5K (+100.0%) | 1.63M +1.6M (+100.0%) | 0.08% +0.084 pp | 0.00% +0.002 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 63 | AMERICAN CENTURY COMPANIES INC | 288.5K +250.0K (+648.4%) | 1.59M +1.5M (+1,158.7%) | 0.08% +0.069 pp | 0.00% +0.001 pp | USD5.20 +5.8% | 2 qtrs — |
| 64 | ENSIGN PEAK ADVISORS, INC | 275.1K +275.1K (+100.0%) | 1.51M +1.5M (+100.0%) | 0.08% +0.078 pp | 0.00% +0.003 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 65 | SWISS NATIONAL BANK | 268.8K +268.8K (+100.0%) | 1.48M +1.5M (+100.0%) | 0.08% +0.076 pp | 0.00% +0.001 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 66 | ORACLE INVESTMENT MANAGEMENT INC | 265.0K +265.0K (+100.0%) | 1.46M +1.5M (+100.0%) | 0.08% +0.075 pp | 0.87% +0.868 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 67 | NOMURA HOLDINGS INC | 259.3K +259.3K (+100.0%) | 1.43M +1.4M (+100.0%) | 0.07% +0.073 pp | 0.00% +0.002 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 68 | RHUMBLINE ADVISERS | 257.4K -31.4K (-10.9%) | 1.42M +471.4K (+49.9%) | 0.07% -0.024 pp | 0.00% +0.000 pp | USD2.41 +128.2% | 7 qtrs — |
| 69 | ALPS ADVISORS INC | 224.9K +224.9K (+100.0%) | 1.24M +1.2M (+100.0%) | 0.06% +0.064 pp | 0.01% +0.007 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 70 | VOYA INVESTMENT MANAGEMENT LLC | 218.2K +181.7K (+497.8%) | 1.20M +1.1M (+905.4%) | 0.06% +0.050 pp | 0.00% +0.001 pp | USD4.96 +10.9% | 7 qtrs — |
| 71 | GSA CAPITAL PARTNERS LLP | 208.0K -269.7K (-56.5%) | 1.14M -418.0K (-26.8%) | 0.06% -0.101 pp | 0.10% -0.032 pp | USD3.18 +73.0% | 3 qtrs — |
| 72 | VICTORY CAPITAL MANAGEMENT INC | 195.8K +170.2K (+664.7%) | 1.08M +993.0K (+1,186.2%) | 0.06% +0.047 pp | 0.00% +0.001 pp | USD5.04 +9.1% | 9 qtrs — |
| 73 | STEMPOINT CAPITAL LP | 182.1K -657.5K (-78.3%) | 1.00M -1.7M (-63.5%) | 0.05% -0.230 pp | 0.17% -0.378 pp | USD2.31 +138.1% | 3 qtrs — |
| 74 | WEXFORD CAPITAL LP | 180.9K +177.4K (+5,067.2%) | 994.7K +983.2K (+8,587.2%) | 0.05% +0.050 pp | 0.19% +0.190 pp | USD5.46 +0.7% | 2 qtrs — |
| 75 | ALLIANCEBERNSTEIN L.P. | 179.6K +— (+0.0%) | 988.0K +400.6K (+68.2%) | 0.05% -0.009 pp | 0.00% +0.000 pp | USD2.26 +143.4% | 7 qtrs — |
| 76 | PALUMBO WEALTH MANAGEMENT LLC | 178.0K +20.7K (+13.1%) | 979.0K +464.5K (+90.3%) | 0.05% -0.002 pp | 0.24% +0.077 pp | USD3.53 +55.8% | 2 qtrs — |
| 77 | BNP PARIBAS ARBITRAGE, SNC | 172.5K +126.4K (+274.7%) | 948.7K +798.1K (+530.2%) | 0.05% +0.033 pp | 0.00% +0.000 pp | USD4.76 +15.5% | 5 qtrs — |
| 78 | RENAISSANCE TECHNOLOGIES LLC | 171.1K +171.1K (+100.0%) | 941.1K +941.1K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.002 pp | USD5.50 +0.0% | 16 qtrs — |
| 79 | AQR CAPITAL MANAGEMENT LLC | 168.9K +17.9K (+11.8%) | 928.7K +435.0K (+88.1%) | 0.05% -0.003 pp | 0.00% +0.000 pp | USD2.24 +145.5% | 6 qtrs — |
| 80 | UBS ASSET MANAGEMENT AMERICAS INC | 167.5K +167.5K (+100.0%) | 921.3K +921.3K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.000 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 81 | PRIVIUM FUND MANAGEMENT B.V. | 164.9K +30.0K (+22.2%) | 907.0K +465.8K (+105.6%) | 0.05% +0.001 pp | 0.17% +0.088 pp | USD2.77 +98.6% | 7 qtrs — |
| 82 | DEUTSCHE BANK AG\ | 160.8K +38.0K (+30.9%) | 884.3K +482.7K (+120.2%) | 0.05% +0.004 pp | 0.00% +0.000 pp | USD3.12 +76.3% | 7 qtrs — |
| 83 | POLEN CAPITAL MANAGEMENT LLC | 156.6K +156.6K (+100.0%) | 861.2K +861.2K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.004 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 84 | CHICAGO PARTNERS INVESTMENT GROUP LLC | 166.5K +2.5K (+1.5%) | 776.1K -42.5K (-5.2%) | 0.05% -0.008 pp | 0.02% -0.002 pp | USD2.77 +98.6% | 10 qtrs — |
| 85 | TWO SIGMA ADVISERS, LP | 139.6K +139.6K (+100.0%) | 767.7K +767.7K (+100.0%) | 0.04% +0.040 pp | 0.00% +0.002 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 86 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 138.6K +128.2K (+1,236.0%) | 762.2K +728.3K (+2,147.0%) | 0.04% +0.036 pp | 0.00% +0.001 pp | USD5.26 +4.6% | 7 qtrs — |
| 87 | LEGAL & GENERAL GROUP PLC | 133.1K +110.0K (+475.2%) | 732.3K +656.6K (+867.4%) | 0.04% +0.030 pp | 0.00% +0.000 pp | USD4.97 +10.7% | 7 qtrs — |
| 88 | PROFUND ADVISORS LLC | 128.6K +75.2K (+141.0%) | 707.2K +532.7K (+305.3%) | 0.04% +0.019 pp | 0.02% +0.016 pp | USD4.38 +25.6% | 5 qtrs — |
| 89 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 122.6K +11.6K (+10.5%) | 677.7K +316.0K (+87.4%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD2.45 +124.5% | 6 qtrs — |
| 90 | PRICE T ROWE ASSOCIATES INC /MD/ | 121.8K +8.0K (+7.0%) | 670.0K +297.0K (+79.6%) | 0.03% -0.004 pp | 0.00% +0.000 pp | USD3.01 +82.7% | 10 qtrs — |
| 91 | METLIFE INVESTMENT MANAGEMENT, LLC | 113.3K -13.8K (-10.8%) | 623.0K +207.5K (+50.0%) | 0.03% -0.011 pp | 0.00% +0.001 pp | USD2.05 +168.3% | 7 qtrs — |
| 92 | STATE OF WISCONSIN INVESTMENT BOARD | 113.2K +70.2K (+163.5%) | 622.5K +482.0K (+343.2%) | 0.03% +0.018 pp | 0.00% +0.001 pp | USD4.65 +18.3% | 2 qtrs — |
| 93 | FRANKLIN RESOURCES INC | 108.4K +— (+0.0%) | 596.2K +241.7K (+68.2%) | 0.03% -0.006 pp | 0.00% +0.000 pp | USD1.39 +295.7% | 6 qtrs — |
| 94 | PRUDENTIAL FINANCIAL INC | 86.7K +58.4K (+206.0%) | 477.0K +384.3K (+414.6%) | 0.02% +0.015 pp | 0.00% +0.001 pp | USD4.58 +20.1% | 10 qtrs — |
| 95 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 85.5K +85.5K (+100.0%) | 470.3K +470.3K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.000 pp | USD5.50 +0.0% | 1 qtrs NEW |
| 96 | JANE STREET GROUP, LLC | 84.8K +71.4K (+532.8%) | 466.4K +422.6K (+964.4%) | 0.02% +0.020 pp | 0.00% +0.000 pp | USD5.00 +10.0% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 96 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 0.93% | 1.98M | 0.50% |
| 2 | Virtus Biotech Clinical Trials ETF BBC | 0.68% | 393.4K | 0.65% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.33% | 117.8K | 0.45% |
| 4 | State Street SPDR S&P Biotech ETF XBI | 0.33% | 35.38M | 0.35% |
| 5 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.17% | 1.93M | 0.40% |
| 6 | iShares Ageing Population UCITS ETF AGED.L | 0.13% | 1.15M | 0.40% |
| 7 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.13% | 579.7K | 0.40% |
| 8 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.13% | 93.6K | 0.19% |
| 9 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.12% | 90.3K | 0.35% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.12% | 1.35M | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.80
Neutral
Ratio by volume
3.00
Bullish
Buys
8
Sells
10
Shares acquired
3.15M
Shares disposed
798.6K
Cash buys
—
Cash sales
8.00
Net activity
+2,348,377
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-10 | Nagendran Sukumar | Director / Officer | M-Exempt | A | Common Stock | 19,021 | 1.71 | 32.5K | 1,336,410 | D | ↗ |
| 2026-02-04 | Alam Kamran | Officer | S-Sale | D | Common Stock | 1,655 | 4.52 | 7.5K | 1,442,131 | D | ↗ |
| 2026-01-26 | Nolan Sean P. | Director / Officer | S-Sale | D | Common Stock | 41,312 | 4.61 | 190.4K | 2,908,257 | D | ↗ |
| 2026-01-26 | Nagendran Sukumar | Director / Officer | S-Sale | D | Common Stock | 26,918 | 4.61 | 124.1K | 1,317,389 | D | ↗ |
| 2026-01-26 | Alam Kamran | Officer | S-Sale | D | Common Stock | 23,849 | 4.61 | 109.9K | 1,443,786 | D | ↗ |
| 2026-01-23 | Nolan Sean P. | Director / Officer | S-Sale | D | Common Stock | 136,789 | 4.75 | 649.7K | 2,949,569 | D | ↗ |
| 2026-01-23 | Nagendran Sukumar | Director / Officer | S-Sale | D | Common Stock | 89,132 | 4.75 | 423.4K | 1,344,307 | D | ↗ |
| 2026-01-23 | Alam Kamran | Officer | S-Sale | D | Common Stock | 78,968 | 4.75 | 375.1K | 1,467,635 | D | ↗ |
| 2026-01-12 | Nolan Sean P. | Director / Officer | A-Award | A | Common Stock | 1,008,000 | 0.00 | — | 3,086,358 | D | ↗ |
| 2026-01-12 | Nagendran Sukumar | Director / Officer | M-Exempt | A | Common Stock | 88,676 | 1.71 | 151.6K | 1,206,439 | D | ↗ |
| 2026-01-12 | Alam Kamran | Officer | A-Award | A | Employee Stock Option (right to buy) | 231,000 | 4.86 | 1.12M | 231,000 | D | ↗ |
| 2025-12-01 | Nagendran Sukumar | Director / Officer | S-Sale | D | Common Stock | 260,047 | 4.51 | 1.17M | 1,006,439 | D | ↗ |
| 2025-11-28 | Nagendran Sukumar | Director / Officer | M-Exempt | D | Employee Stock Option (right to buy) | 70,172 | 0.70 | 49.0K | 222,683 | D | ↗ |
| 2025-09-10 | Nagendran Sukumar | Director / Officer | M-Exempt | A | Common Stock | 41,150 | 0.70 | 28.8K | 1,206,439 | D | ↗ |
| 2025-08-21 | Nagendran Sukumar | Director / Officer | S-Sale | D | Common Stock | 57,054 | 2.85 | 162.6K | 1,165,289 | D | ↗ |
| 2025-08-21 | Alam Kamran | Officer | S-Sale | D | Common Stock | 54,491 | 2.85 | 155.3K | 1,187,603 | D | ↗ |
| 2025-06-02 | Stalfort John A III | Director | A-Award | A | Stock Option (right to buy) | 113,246 | 2.79 | 315.4K | 113,246 | D | ↗ |
| 2025-06-02 | Sepp-Lorenzino Laura | Director | A-Award | A | Common Stock | 56,623 | 0.00 | — | 105,843 | D | ↗ |
| 2025-06-02 | Long Alison S | Director | A-Award | A | Stock Option (right to buy) | 113,246 | 2.79 | 315.4K | 113,246 | D | ↗ |
| 2025-06-02 | Donenberg Phillip B. | Director | A-Award | A | Common Stock | 56,623 | 0.00 | — | 219,954 | D | ↗ |
| 2025-05-30 | Manning Paul B | 10% Owner | P-Purchase | A | Common Stock | 750,000 | 2.75 | 2.06M | 2,841,704 | I | ↗ |
| 2025-03-11 | Alam Kamran | Officer | F-InKind | D | Common Stock | 29,843 | 1.69 | 50.4K | 1,242,094 | D | ↗ |
| 2025-01-02 | Nolan Sean P. | Director / Officer | A-Award | A | Common Stock | 892,500 | 0.00 | — | 2,078,358 | D | ↗ |
| 2025-01-02 | Nagendran Sukumar | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 324,500 | 1.85 | 600.3K | 324,500 | D | ↗ |
| 2025-01-02 | Alam Kamran | Officer | A-Award | A | Employee Stock Option (right to buy) | 431,000 | 1.85 | 797.4K | 431,000 | D | ↗ |
| 2024-06-27 | Manning Paul B | 10% Owner | P-Purchase | A | Common Stock | 1,333,333 | 2.25 | 3.00M | 1,333,333 | — | ↗ |
| 2024-05-29 | Stalfort John A III | Director | A-Award | A | Stock Option (right to buy) | 98,440 | 3.17 | 312.1K | 98,440 | — | ↗ |
| 2024-05-29 | Sepp-Lorenzino Laura | Director | A-Award | A | Stock Option (right to buy) | 98,440 | 3.17 | 312.1K | 98,440 | — | ↗ |
| 2024-05-29 | Long Alison S | Director | A-Award | A | Common Stock | 49,220 | 0.00 | — | 49,220 | — | ↗ |
| 2024-05-29 | Donenberg Phillip B. | Director | A-Award | A | Common Stock | 49,220 | 0.00 | — | 163,331 | — | ↗ |
| 2024-02-02 | Alam Kamran | Officer | F-InKind | D | Common Stock | 1,288 | 1.51 | 1.9K | 840,937 | — | ↗ |
| 2024-01-02 | Nolan Sean P. | Director / Officer | A-Award | A | Common Stock | 1,184,688 | 0.00 | — | 1,185,858 | — | ↗ |
| 2024-01-02 | Nagendran Sukumar | Director / Officer | A-Award | A | Common Stock | 863,617 | 0.00 | — | 897,843 | — | ↗ |
| 2024-01-02 | Alam Kamran | Officer | A-Award | A | Common Stock | 590,413 | 0.00 | — | 842,225 | — | ↗ |
| 2023-12-14 | Nolan Sean P. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 466,550 | 0.70 | 326.1K | 466,550 | — | ↗ |
| 2023-12-14 | Nagendran Sukumar | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 334,005 | 0.70 | 233.4K | 334,005 | — | ↗ |
| 2023-12-14 | Alam Kamran | Officer | A-Award | A | Employee Stock Option (right to buy) | 187,582 | 0.70 | 131.1K | 187,582 | — | ↗ |
| 2023-11-17 | Manning Paul B | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 1.63 | 163.0K | 16,566,667 | — | ↗ |
| 2023-11-01 | Long Alison S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-24 | Alam Kamran | Officer | S-Sale | D | Common Stock | 33,000 | 2.33 | 76.9K | 258,042 | — | ↗ |
| 2023-08-16 | Stalfort John A III | Director | G-Gift | A | Common Stock | 50,000 | 0.00 | — | 1,049,381 | — | ↗ |
| 2023-08-16 | Nolan Sean P. | Director / Officer | P-Purchase | A | Common Stock | 444,444 | 0.90 | 400.0K | 1,535,545 | — | ↗ |
| 2023-08-16 | Manning Paul B | 10% Owner | P-Purchase | A | Common Stock | 16,466,667 | 0.90 | 14.82M | 16,466,667 | — | ↗ |
| 2023-08-16 | Donenberg Phillip B. | Director | P-Purchase | A | Common Stock | 111,111 | 0.90 | 100.0K | 114,111 | — | ↗ |
| 2023-07-13 | Session R.A. II | 10% Owner | S-Sale | D | Common Stock | 5,344 | 0.70 | 3.7K | 8,871,747 | — | ↗ |
| 2023-07-12 | Session R.A. II | 10% Owner | S-Sale | D | Common Stock | 80,528 | 0.71 | 57.0K | 8,877,091 | — | ↗ |
| 2023-06-23 | Session R.A. II | 10% Owner | S-Sale | D | Common Stock | 18,100 | 0.70 | 12.7K | 8,957,619 | — | ↗ |
| 2023-06-22 | Stalfort John A III | Director | A-Award | A | Stock Option (right to buy) | 43,800 | 0.72 | 31.5K | 43,800 | — | ↗ |
| 2023-06-22 | Session R.A. II | 10% Owner | S-Sale | D | Common Stock | 10,508 | 0.70 | 7.4K | 8,975,719 | — | ↗ |
| 2023-06-22 | Sepp-Lorenzino Laura | Director | A-Award | A | Stock Option (right to buy) | 36,200 | 0.72 | 26.1K | 36,200 | — | ↗ |
| 2023-06-22 | Reape Kathleen | Director | A-Award | A | Stock Option (right to buy) | 36,200 | 0.72 | 26.1K | 36,200 | — | ↗ |
| 2023-06-22 | Donenberg Phillip B. | Director | A-Award | A | Stock Option (right to buy) | 36,200 | 0.72 | 26.1K | 36,200 | — | ↗ |
| 2023-06-21 | Session R.A. II | 10% Owner | S-Sale | D | Common Stock | 138,962 | 0.70 | 97.6K | 8,986,227 | — | ↗ |
| 2023-06-20 | Session R.A. II | 10% Owner | S-Sale | D | Common Stock | 295,653 | 0.71 | 210.2K | 9,125,189 | — | ↗ |
| 2023-05-31 | Alam Kamran | Officer | A-Award | A | Common Stock | 6,230 | 0.00 | — | 291,042 | — | ↗ |
| 2023-05-16 | Nagendran Sukumar | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 0.68 | 3.4K | 34,226 | — | ↗ |
| 2023-03-06 | Session R.A. II | 10% Owner | D-Return | D | Employee Stock Option (right to buy) | 199,500 | 1.95 | 389.0K | 0 | — | ↗ |
| 2023-02-02 | Alam Kamran | Officer | A-Award | A | Common Stock | 18,691 | 0.00 | — | 284,812 | — | ↗ |
| 2022-12-30 | Nolan Sean P. | Officer | A-Award | A | Stock Option (right to buy) | 1,106,131 | 0.00 | — | 1,106,131 | — | ↗ |
| 2022-12-30 | Nagendran Sukumar | Officer | A-Award | A | Stock Option (right to buy) | 790,093 | 0.00 | — | 790,093 | — | ↗ |
| 2022-11-10 | Session R.A. II | Director | A-Award | A | Employee Stock Option (right to buy) | 199,500 | 0.00 | — | 199,500 | — | ↗ |
| 2022-10-31 | Manning Paul B | Director | P-Purchase | A | Common Stock | 1,500,000 | 2.00 | 3.00M | 1,642,202 | — | ↗ |
| 2022-10-21 | Audentes Therapeutics, Inc. | Director | — | D | Common Stock | 0 | 0.00 | — | 7,266,342 | — | ↗ |
| 2022-08-23 | Alam Kamran | Officer | S-Sale | D | Common Stock | 3,325 | 3.47 | 11.5K | 266,121 | — | ↗ |
| 2022-08-22 | Alam Kamran | Officer | S-Sale | D | Common Stock | 9,717 | 3.50 | 34.0K | 269,446 | — | ↗ |
| 2022-08-18 | Alam Kamran | Officer | S-Sale | D | Common Stock | 7,476 | 3.87 | 28.9K | 290,645 | — | ↗ |
| 2022-07-05 | PRASAD SUYASH | Officer | S-Sale | D | Common Stock | 3,905 | 3.51 | 13.7K | 539,545 | — | ↗ |
| 2022-06-29 | PRASAD SUYASH | Officer | S-Sale | D | Common Stock | 12,324 | 3.81 | 47.0K | 581,265 | — | ↗ |
| 2022-06-17 | Sepp-Lorenzino Laura | Director | A-Award | A | Stock Option (right to buy) | 15,500 | 0.00 | — | 15,500 | — | ↗ |
| 2022-06-17 | Reape Kathleen | Director | A-Award | A | Stock Option (right to buy) | 15,500 | 0.00 | — | 15,500 | — | ↗ |
| 2022-06-17 | Nolan Sean P. | Director | A-Award | A | Stock Option (right to buy) | 15,500 | 0.00 | — | 15,500 | — | ↗ |
| 2022-06-17 | Nagendran Sukumar | Director | A-Award | A | Stock Option (right to buy) | 15,500 | 0.00 | — | 15,500 | — | ↗ |
| 2022-06-17 | Manning Paul B | Director | A-Award | A | Stock Option (right to buy) | 15,500 | 0.00 | — | 15,500 | — | ↗ |
| 2022-06-17 | Donenberg Phillip B. | Director | A-Award | A | Stock Option (right to buy) | 15,500 | 0.00 | — | 15,500 | — | ↗ |
| 2022-04-06 | PRASAD SUYASH | Officer | A-Award | A | Employee Stock Option (right to buy) | 40,325 | 0.00 | — | 40,325 | — | ↗ |
| 2022-04-06 | Alam Kamran | Officer | A-Award | A | Employee Stock Option (right to buy) | 40,000 | 6.52 | 260.8K | 40,000 | — | ↗ |
| 2022-02-23 | Session R.A. II | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 217,850 | 5.96 | 1.30M | 217,850 | — | ↗ |
| 2022-02-23 | PRASAD SUYASH | Officer | A-Award | A | Employee Stock Option (right to buy) | 80,650 | 5.96 | 480.7K | 80,650 | — | ↗ |
| 2022-02-23 | Alam Kamran | Officer | A-Award | A | Employee Stock Option (right to buy) | 80,000 | 5.96 | 476.8K | 80,000 | — | ↗ |
| 2022-02-03 | Manning Paul B | Director / 10% Owner | P-Purchase | A | Common Stock | 26,602 | 7.84 | 208.6K | 2,091,704 | — | ↗ |
| 2022-02-02 | Nagendran Sukumar | Director | P-Purchase | A | Common Stock | 10,000 | 8.01 | 80.1K | 29,226 | — | ↗ |
| 2022-02-02 | Manning Paul B | Director / 10% Owner | P-Purchase | A | Common Stock | 45,000 | 7.77 | 349.7K | 2,065,102 | — | ↗ |
| 2022-02-02 | Donenberg Phillip B. | Director | P-Purchase | A | Common Stock | 3,000 | 7.78 | 23.3K | 3,000 | — | ↗ |
| 2021-11-24 | Manning Paul B | Director / 10% Owner | P-Purchase | A | Common Stock | 2,202 | 13.19 | 29.0K | 34,202 | — | ↗ |
| 2021-11-23 | Session R.A. II | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 26,008 | 12.65 | 329.0K | 9,190,920 | — | ↗ |
| 2021-11-23 | Manning Paul B | Director / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 12.54 | 250.8K | 32,000 | — | ↗ |
| 2021-08-20 | Alam Kamran | Officer | S-Sale | D | Common Stock | 9,746 | 16.70 | 162.8K | 300,215 | — | ↗ |
| 2021-08-19 | Alam Kamran | Officer | S-Sale | D | Common Stock | 9,354 | 16.43 | 153.7K | 310,574 | — | ↗ |
| 2021-08-18 | Alam Kamran | Officer | S-Sale | D | Common Stock | 11,193 | 17.35 | 194.2K | 319,928 | — | ↗ |
| 2021-07-01 | PRASAD SUYASH | Officer | S-Sale | D | Common Stock | 19,706 | 21.12 | 416.2K | 593,589 | — | ↗ |
| 2021-06-30 | PRASAD SUYASH | Officer | S-Sale | D | Common Stock | 500 | 23.70 | 11.9K | 613,295 | — | ↗ |
| 2021-06-29 | PRASAD SUYASH | Officer | S-Sale | D | Common Stock | 300 | 25.19 | 7.6K | 633,371 | — | ↗ |
| 2021-06-17 | Sepp-Lorenzino Laura | Director | A-Award | A | Stock Option (right to buy) | 15,500 | 25.04 | 388.1K | 15,500 | — | ↗ |
| 2021-06-17 | Reape Kathleen | Director | A-Award | A | Stock Option (right to buy) | 15,500 | 25.04 | 388.1K | 15,500 | — | ↗ |
| 2021-06-17 | Nolan Sean P. | Director | A-Award | A | Stock Option (right to buy) | 15,500 | 25.04 | 388.1K | 15,500 | — | ↗ |
| 2021-06-17 | Nagendran Sukumar | Director | A-Award | A | Stock Option (right to buy) | 15,500 | 25.04 | 388.1K | 15,500 | — | ↗ |
| 2021-06-17 | Manning Paul B | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 15,500 | 25.04 | 388.1K | 15,500 | — | ↗ |
| 2021-06-17 | Donenberg Phillip B. | Director | A-Award | A | Stock Option (right to buy) | 15,500 | 25.04 | 388.1K | 15,500 | — | ↗ |
| 2021-05-20 | Nolan Sean P. | Director | P-Purchase | A | Common Stock | 1,170 | 22.35 | 26.1K | 1,170 | — | ↗ |
| 2021-05-14 | Manning Paul B | Director / 10% Owner | P-Purchase | A | Common Stock | 12,000 | 20.98 | 251.8K | 12,000 | — | ↗ |
| 2021-01-19 | Session R.A. II | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 199,700 | 31.00 | 6.19M | 199,700 | — | ↗ |
| 2021-01-19 | PRASAD SUYASH | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 31.00 | 2.48M | 80,000 | — | ↗ |
| 2021-01-19 | Alam Kamran | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 31.00 | 2.17M | 70,000 | — | ↗ |
| 2020-12-31 | Manning Paul B | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,020,102 | — | ↗ |
| 2020-11-23 | Sepp-Lorenzino Laura | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 21.77 | 674.9K | 31,000 | — | ↗ |
| 2020-11-23 | Reape Kathleen | Director | A-Award | A | Stock Option (right to buy) | 31,000 | 21.77 | 674.9K | 31,000 | — | ↗ |
| 2020-09-28 | PRASAD SUYASH | Officer | C-Conversion | A | Common Stock | 3,844 | 0.00 | — | 672,589 | — | ↗ |
| 2020-09-28 | Nolan Sean P. | Director | C-Conversion | D | Series B Preferred Stock | 1,470 | 0.00 | — | 0 | — | ↗ |
| 2020-09-28 | Nagendran Sukumar | Director | C-Conversion | A | Common Stock | 19,226 | 0.00 | — | 19,226 | — | ↗ |
| 2020-09-28 | Manning Paul B | Director / 10% Owner | C-Conversion | D | Series A Preferred Stock | 1,843,193 | 0.00 | — | 0 | — | ↗ |
| 2020-09-23 | Session R.A. II | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 141,090 | — | ↗ |
| 2020-09-23 | PRASAD SUYASH | Officer | — | D | Series B Preferred Stock | 3,844 | 0.00 | — | 0 | — | ↗ |
| 2020-09-23 | Nolan Sean P. | Director | — | I | Series B Preferred Stock | 1,601 | 0.00 | — | 0 | — | ↗ |
| 2020-09-23 | Nagendran Sukumar | Director | — | D | Stock Option (right to buy) | 8,171 | 14.90 | 121.7K | 0 | — | ↗ |
| 2020-09-23 | Manning Paul B | Director / 10% Owner | — | I | Series A Preferred Stock | 2,008,158 | 0.00 | — | 0 | — | ↗ |
| 2020-09-23 | Donenberg Phillip B. | Director | — | D | Stock Option (right to buy) | 8,171 | 14.90 | 121.7K | 0 | — | ↗ |
| 2020-09-23 | Alam Kamran | Officer | A-Award | A | Common Stock | 331,121 | 0.00 | — | 331,121 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-14.9K
Shares Outstanding
287.34M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Sean Nolan Chief Executive Officer and Director | 645.8K | — | 1.65M | 1.26M | 542.5K | 1.2K | 4.10M | 70.98% | ↗ |
| 2 | 2025 | Kamran Alam Chief Financial Officer | 473.3K | — | 797.4K | 607.7K | 265.1K | 3.5K | 2.15M | 65.44% | ↗ |
| 3 | 2025 | Sukumar Nagendran, M.D. President and Head of Research and Development and Director | 608.2K | — | 600.3K | 457.5K | 425.7K | 1.1K | 2.09M | 50.55% | ↗ |
| 4 | 2024 | Sean Nolan Chief Executive Officer and Director | 621.0K | — | 2.03M | 1.67M | 409.9K | 774.00 | 4.73M | 78.18% | ↗ |
| 5 | 2024 | Sukumar Nagendran, M.D. President and Head of Research and Development | 584.8K | — | 1.48M | 1.22M | 321.6K | 774.00 | 3.60M | 74.81% | ↗ |
| 6 | 2024 | Sukumar Nagendran, M.D. President and Head of Research and Development and Director | 584.8K | — | 1.48M | 1.22M | 321.6K | 774.00 | 3.60M | 74.81% | ↗ |
| 7 | 2024 | Kamran Alam Chief Financial Officer | 455.1K | — | 1.01M | 832.5K | 210.9K | 10.6K | 2.52M | 73.13% | ↗ |
| 8 | 2023 | Sean Nolan Chief Executive Officer and Director | 600.0K | — | — | 597.2K | 324.0K | 1.3K | 1.52M | 39.22% | ↗ |
| 9 | 2023 | Sukumar Nagendran, M.D. President and Head of Research and Development | 565.0K | — | — | 427.5K | 254.3K | 1.3K | 1.25M | 34.25% | ↗ |
| 10 | 2023 | Kamran Alam Chief Financial Officer | 413.8K | — | — | 402.0K | 149.0K | 10.7K | 975.4K | 41.22% | ↗ |
| 11 | 2022 | RA Session II Former President, Chief Executive Officer and Director | 537.9K | 271.4K | — | 1.15M | — | 173.00 | 1.96M | 58.77% | ↗ |
| 12 | 2022 | Sean Nolan Chief Executive Officer and Director | 25.0K | — | — | 1.80M | — | 74.0K | 1.90M | 94.79% | ↗ |
| 13 | 2022 | Sukumar Nagendran, MD President and Head of Research and Development | 23.5K | — | — | 1.29M | — | 54.1K | 1.36M | 94.31% | ↗ |
| 14 | 2022 | Sukumar Nagendran, M.D. President and Head of Research and Development | 23.5K | — | — | 1.29M | — | 54.1K | 1.36M | 94.31% | ↗ |
| 15 | 2022 | Kamran Alam Chief Financial Officer | 401.7K | 156.0K | — | 498.2K | 136.6K | 9.3K | 1.20M | 41.45% | ↗ |
| 16 | 2021 | RA Session II Former President, Chief Executive Officer and Director | 542.8K | — | — | 4.03M | — | 150.00 | 4.57M | 88.12% | ↗ |
| 17 | 2021 | RA Session II President, Chief Executive Officer and Director | 542.8K | — | — | 4.03M | — | 150.00 | 4.57M | 88.12% | ↗ |
| 18 | 2021 | Suyash Prasad, M.B.B.S, F.F.P.M. Chief Medical Officer and Head of Research and Development | 432.6K | — | — | 1.61M | 181.7K | 3.1K | 2.23M | 72.33% | ↗ |
| 19 | 2021 | Kamran Alam Chief Financial Officer | 390.0K | — | — | 1.41M | — | 5.5K | 1.81M | 78.12% | ↗ |
| 20 | 2020 | Kamran Alam Chief Financial Officer | 142.1K | — | 4.93M | — | 85.2K | 330.2K | 5.49M | 89.85% | ↗ |
| 21 | 2020 | RA Session II President, Chief Executive Officer and Director | 362.6K | — | 4.06M | — | 271.9K | 154.00 | 4.70M | 86.48% | ↗ |
| 22 | 2020 | Suyash Prasad, M.B.B.S, F.F.P.M. Chief Medical Officer and Head of Research and Development | 216.8K | — | 3.67M | — | 130.0K | 152.00 | 4.02M | 91.36% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sean Nolan | Chief Executive Officer & Chairman | 1M | male |
| Sukumar Nagendran | President, Head of Research & Development and Director | 1M | — |
| Kamran Alam | Chief Financial Officer & Corporate Secretary | 741.9K | male |
| Frederick Porter | Chief of Staff & Technical Operations Officer | — | male |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations | — | — |
| Rumana Haque-Ahmed | Chief Regulatory Officer | — | female |
| Sean McAuliffe | Chief Business Officer | — | male |
| Steven Gray | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | — | — |
| Berge Minassian | Chief Medical Advisor of UT Southwestern Gene Therapy Program | — | — |
| Tracy Porter | Chief People Officer | — | female |
| David McNinch | Chief Commercial Officer | — | male |
| Emily McGinnis | Chief Patient & External Affairs Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TSHA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
